Skip to main content
Top
Published in: Health Research Policy and Systems 1/2010

Open Access 01-12-2010 | Research

"We noticed that suddenly the country has become full of MRI". Policy makers' views on diffusion and use of health technologies in Iran

Authors: Mohammad Palesh, Carol Tishelman, Sten Fredrikson, Hamidreza Jamshidi, Göran Tomson, Azita Emami

Published in: Health Research Policy and Systems | Issue 1/2010

Login to get access

Abstract

Objective

Uncontrolled proliferation of health technologies (HT) is one contributor to the increasing pressure on health systems to adopt new technologies. With limited resources, policy-makers encounter difficulties in fulfilling their responsibility to meet the healthcare needs of the population. The aim of this study is to explore how policy-makers' reason about the diffusion and utilization of health technologies in Iran using magnetic resonance imaging (MRI) and interferon beta as tracers.

Method

This qualitative exploration complements quantitative data generated in a research project investigating the diffusion and utilization of MRI and interferon beta in Iran. Qualitative semi-structured interviews were conducted with 13 informants in different positions and levels of authority in the Ministry of Health (MOH), University of Medical Sciences, Health Insurance Organizations, and Parliament. The data was analysed using the framework approach.

Findings

Although policy-makers appeared to be positive to health technology assessment (HTA), the processes of policy-making described by the interviewees did not seem to be based on a full understanding of this (discipline). Several obstacles to applying knowledge about HT and HTA were described. The current official plan for MRI adoption and diffusion in the country was said not to be followed, and no such plan was described for interferon beta. Instead, market forces such as advertising, and physician and consumer demand, appear to have strong influence on HT diffusion and use. Dual practice may have increased the induced demand and also reduced the supervision of the private sector by the MOH.

Conclusion

Management instability and lack of coordination in the MOH were found to be important obstacles to accumulation of knowledge and experience which, in turn, could have led to suboptimal managerial and policy-making processes. Furthermore marketing should be controlled in order to avoid creating unnecessary patient demands and negative influences on physicians' behavior.
Appendix
Available only for authorised users
Literature
2.
go back to reference Levin L, Goeree R, Sikich N, Jorgensen B, Brouwers MC, Easty T, Zahn C: Establishing a comprehensive continuum from an evidentiary base to policy development for health technologies: the Ontario experience. Int J Technol Assess Health Care. 2007, 23 (3): 299-309. 10.1017/S0266462307070456.CrossRefPubMed Levin L, Goeree R, Sikich N, Jorgensen B, Brouwers MC, Easty T, Zahn C: Establishing a comprehensive continuum from an evidentiary base to policy development for health technologies: the Ontario experience. Int J Technol Assess Health Care. 2007, 23 (3): 299-309. 10.1017/S0266462307070456.CrossRefPubMed
3.
go back to reference Basch PF: Technology transfer to the developing world: does new technology have any relevance for developing countries?. Tuber Lung Dis. 1993, 74 (6): 353-358. 10.1016/0962-8479(93)90077-B.CrossRefPubMed Basch PF: Technology transfer to the developing world: does new technology have any relevance for developing countries?. Tuber Lung Dis. 1993, 74 (6): 353-358. 10.1016/0962-8479(93)90077-B.CrossRefPubMed
6.
go back to reference Hanney S, Buxton M, Green C, Coulson D, Raftery J: An assessment of the impact of the NHS Health Technology Assessment Programme. Health Technol Assess. 2007, 11 (53): 1-200.CrossRef Hanney S, Buxton M, Green C, Coulson D, Raftery J: An assessment of the impact of the NHS Health Technology Assessment Programme. Health Technol Assess. 2007, 11 (53): 1-200.CrossRef
7.
go back to reference Banta D, Jonsson E: History of HTA: Introduction. Int J Technol Assess Health Care. 2009, 25 (Suppl 1): 1-6. 10.1017/S0266462309090321.CrossRefPubMed Banta D, Jonsson E: History of HTA: Introduction. Int J Technol Assess Health Care. 2009, 25 (Suppl 1): 1-6. 10.1017/S0266462309090321.CrossRefPubMed
8.
go back to reference Palesh M, Fredrikson S, Jamshidi H, Jonsson PM, Tomson G: Diffusion of magnetic resonance imaging in Iran. Int J Technol Assess Health Care. 2007, 23 (2): 278-285. 10.1017/S0266462307070377.CrossRefPubMed Palesh M, Fredrikson S, Jamshidi H, Jonsson PM, Tomson G: Diffusion of magnetic resonance imaging in Iran. Int J Technol Assess Health Care. 2007, 23 (2): 278-285. 10.1017/S0266462307070377.CrossRefPubMed
9.
go back to reference Palesh M, Fredrikson S, Jamshidi H, Tomson G, Petzold M: How is magnetic resonance imaging used in Iran?. Int J Technol Assess Health Care. 2008, 24 (4): 452-458. 10.1017/S0266462308080598.CrossRefPubMed Palesh M, Fredrikson S, Jamshidi H, Tomson G, Petzold M: How is magnetic resonance imaging used in Iran?. Int J Technol Assess Health Care. 2008, 24 (4): 452-458. 10.1017/S0266462308080598.CrossRefPubMed
10.
go back to reference Palesh M, Jonsson PM, Jamshidi H, Wettermark B, Tomson G, Fredrikson S: Diffusion of interferon beta in Iran and its utilization in Tehran. Pharmacoepidemiol Drug Saf. 2008, 17 (9): 934-941. 10.1002/pds.1621.CrossRefPubMed Palesh M, Jonsson PM, Jamshidi H, Wettermark B, Tomson G, Fredrikson S: Diffusion of interferon beta in Iran and its utilization in Tehran. Pharmacoepidemiol Drug Saf. 2008, 17 (9): 934-941. 10.1002/pds.1621.CrossRefPubMed
11.
go back to reference Banta D, Luce B: Health Care Technology and its Assessment: An International Perspective. 1993, Oxford University Press Banta D, Luce B: Health Care Technology and its Assessment: An International Perspective. 1993, Oxford University Press
12.
go back to reference Goodin DS, Frohman EM, Garmany GP, Halper J, Likosky WH, Lublin FD, Silberberg DH, Stuart WH, Noort S: Disease modifying therapies in multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology. 2002, 58 (2): 169-178.CrossRefPubMed Goodin DS, Frohman EM, Garmany GP, Halper J, Likosky WH, Lublin FD, Silberberg DH, Stuart WH, Noort S: Disease modifying therapies in multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology. 2002, 58 (2): 169-178.CrossRefPubMed
15.
go back to reference Deputy for Food and Drug, Ministry of Health and Medical Education, Iran: National Drug Policy Islamic Republic of Iran. 2004 Deputy for Food and Drug, Ministry of Health and Medical Education, Iran: National Drug Policy Islamic Republic of Iran. 2004
16.
go back to reference Nikfar S, Kebriaeezadeh A, Majdzadeh R, Abdollahi M: Monitoring of National Drug Policy (NDP) and its standardized indicators; conformity to decisions of the national drug selecting committee in Iran. BMC Int Health Hum Rights. 2005, 5 (1): 5-10.1186/1472-698X-5-5.CrossRefPubMedPubMedCentral Nikfar S, Kebriaeezadeh A, Majdzadeh R, Abdollahi M: Monitoring of National Drug Policy (NDP) and its standardized indicators; conformity to decisions of the national drug selecting committee in Iran. BMC Int Health Hum Rights. 2005, 5 (1): 5-10.1186/1472-698X-5-5.CrossRefPubMedPubMedCentral
17.
go back to reference World Health Organization: Health system profile, IR of Iran. Eastern Mediterranean Region Office (EMRO). 2004 World Health Organization: Health system profile, IR of Iran. Eastern Mediterranean Region Office (EMRO). 2004
18.
go back to reference Robson C: Real world research. 2002, Massachusetts: Blackwell Robson C: Real world research. 2002, Massachusetts: Blackwell
19.
go back to reference Patton MQ: Qualitative research and evaluation methods. 2002, London: SAGE Patton MQ: Qualitative research and evaluation methods. 2002, London: SAGE
20.
go back to reference Green J: Qualitative Methods for Health Research. 2004, London: SAGE Green J: Qualitative Methods for Health Research. 2004, London: SAGE
21.
go back to reference Ritchie J, Lewis J: Qualitative Research Practice. A Guide for Social Science Students and Researchers. 2003, London: SAGE Ritchie J, Lewis J: Qualitative Research Practice. A Guide for Social Science Students and Researchers. 2003, London: SAGE
23.
go back to reference Corabian P, Hailey D, Harstall C, Juzwishin D, Moga C: Mentoring a developing health technology assessment initiative in Romania: an example for countries with limited experience of assessing health technology. Int J Technol Assess Health Care. 2005, 21 (4): 522-525. 10.1017/S0266462305050737.CrossRefPubMed Corabian P, Hailey D, Harstall C, Juzwishin D, Moga C: Mentoring a developing health technology assessment initiative in Romania: an example for countries with limited experience of assessing health technology. Int J Technol Assess Health Care. 2005, 21 (4): 522-525. 10.1017/S0266462305050737.CrossRefPubMed
24.
go back to reference Malterud K: Qualitative research: standards, challenges, and guidelines. Lancet. 2001, 358 (9280): 483-488. 10.1016/S0140-6736(01)05627-6.CrossRefPubMed Malterud K: Qualitative research: standards, challenges, and guidelines. Lancet. 2001, 358 (9280): 483-488. 10.1016/S0140-6736(01)05627-6.CrossRefPubMed
25.
go back to reference European Observatory on Health Systems and Policies: Health Technology Assessment and Health Policy-Making in Europe: Current status, Challenges and Potential. 2008 European Observatory on Health Systems and Policies: Health Technology Assessment and Health Policy-Making in Europe: Current status, Challenges and Potential. 2008
26.
go back to reference European Observatory on Health Systems and Policies: Health Technology Assessment: An introduction to objectives, role of evidence, and structure in Europe. 2005 European Observatory on Health Systems and Policies: Health Technology Assessment: An introduction to objectives, role of evidence, and structure in Europe. 2005
27.
go back to reference Gilson L, McIntyre D: The interface between research and policy: Experience from South Africa. Soc Sci Med. 2008, 67: 748-759. 10.1016/j.socscimed.2008.02.005.CrossRefPubMed Gilson L, McIntyre D: The interface between research and policy: Experience from South Africa. Soc Sci Med. 2008, 67: 748-759. 10.1016/j.socscimed.2008.02.005.CrossRefPubMed
29.
go back to reference Hivon M, Lehoux P, Denis JL, Tailliez S: Use of health technology assessment in decision making: Coresponsibility of users and producers?. International Journal of Technology Assessment in Health Care. 2005, 21 (2): 268-275.PubMed Hivon M, Lehoux P, Denis JL, Tailliez S: Use of health technology assessment in decision making: Coresponsibility of users and producers?. International Journal of Technology Assessment in Health Care. 2005, 21 (2): 268-275.PubMed
30.
go back to reference Buse K, Walt G: Aid coordination for health sector reform: a conceptual framework for analysis and assessment. Health Policy. 1996, 38: 173-187. 10.1016/0168-8510(96)00855-X.CrossRefPubMed Buse K, Walt G: Aid coordination for health sector reform: a conceptual framework for analysis and assessment. Health Policy. 1996, 38: 173-187. 10.1016/0168-8510(96)00855-X.CrossRefPubMed
31.
go back to reference Garcia-Prado A, Gonzalez P: Policy and regulatory responses to dual practice in the health sector. Health Policy. 2007, 84 (2-3): 142-152. 10.1016/j.healthpol.2007.03.006.CrossRefPubMed Garcia-Prado A, Gonzalez P: Policy and regulatory responses to dual practice in the health sector. Health Policy. 2007, 84 (2-3): 142-152. 10.1016/j.healthpol.2007.03.006.CrossRefPubMed
32.
go back to reference Ferrinho P, Van Lerberghe W, Fronteira I, Hipolito F, Biscaia A: Dual practice in the health sector: review of the evidence. Hum Resour Health. 2004, 2 (1): 14-10.1186/1478-4491-2-14.CrossRefPubMedPubMedCentral Ferrinho P, Van Lerberghe W, Fronteira I, Hipolito F, Biscaia A: Dual practice in the health sector: review of the evidence. Hum Resour Health. 2004, 2 (1): 14-10.1186/1478-4491-2-14.CrossRefPubMedPubMedCentral
33.
go back to reference Mansfield PR, Lexchin J, Wen LS, Grandori L, McCoy CP, Hoffman JR, Ramos J, Jureidini JN: Educating health professionals about drug and device promotion: Advocates recommendations. PLos Med. 2006, 3 (11): 1988-1991. 10.1371/journal.pmed.0030451.CrossRef Mansfield PR, Lexchin J, Wen LS, Grandori L, McCoy CP, Hoffman JR, Ramos J, Jureidini JN: Educating health professionals about drug and device promotion: Advocates recommendations. PLos Med. 2006, 3 (11): 1988-1991. 10.1371/journal.pmed.0030451.CrossRef
34.
go back to reference Walt G, Gilson L: Reforming the health sector in developing countries: the central role of policy analysis. Health Policy Plan. 1994, 9 (4): 353-370. 10.1093/heapol/9.4.353.CrossRefPubMed Walt G, Gilson L: Reforming the health sector in developing countries: the central role of policy analysis. Health Policy Plan. 1994, 9 (4): 353-370. 10.1093/heapol/9.4.353.CrossRefPubMed
35.
go back to reference Eggleston K, Bir A: Physician dual practice. Health Policy. 2006, 78: 157-166. 10.1016/j.healthpol.2005.09.007.CrossRefPubMed Eggleston K, Bir A: Physician dual practice. Health Policy. 2006, 78: 157-166. 10.1016/j.healthpol.2005.09.007.CrossRefPubMed
36.
go back to reference Gallego G, Gool VK, Kelleher D: Resource allocation and health technology assessment in Australia: Views from the local level. Int J Technol Assess Health Care. 2009, 25 (2): 134-140. 10.1017/S0266462309090187.CrossRefPubMed Gallego G, Gool VK, Kelleher D: Resource allocation and health technology assessment in Australia: Views from the local level. Int J Technol Assess Health Care. 2009, 25 (2): 134-140. 10.1017/S0266462309090187.CrossRefPubMed
37.
go back to reference Perleth M, Gibis B, Gohlen B: A short history of health technology assessment in Germany. Int J Technol Assess Health Care. 2009, 25 (Suppl 1): 112-119. 10.1017/S0266462309090515.CrossRefPubMed Perleth M, Gibis B, Gohlen B: A short history of health technology assessment in Germany. Int J Technol Assess Health Care. 2009, 25 (Suppl 1): 112-119. 10.1017/S0266462309090515.CrossRefPubMed
38.
go back to reference Rosenau PV: Managing medical technology: lessons for the United States from Quebec and France. International Journal of Health Services. 2000, 30 (3): 617-639. 10.2190/20H5-9N3J-1WC4-NXP7.CrossRefPubMed Rosenau PV: Managing medical technology: lessons for the United States from Quebec and France. International Journal of Health Services. 2000, 30 (3): 617-639. 10.2190/20H5-9N3J-1WC4-NXP7.CrossRefPubMed
39.
go back to reference Trubswasser U, Branca F: Nutrition policy is taking shape in Europe. Public Health Nutrition. 2009, 12 (3): 295-306.CrossRefPubMed Trubswasser U, Branca F: Nutrition policy is taking shape in Europe. Public Health Nutrition. 2009, 12 (3): 295-306.CrossRefPubMed
40.
go back to reference Stenson B, Syhakhang L, Lundborg CS, Eriksson B, Tomson G: Private pharmacy practice and regulation. A randomized trial in Lao P.D.R. Int J Technol Assess Health Care. 2001, 17 (4): 579-589.PubMed Stenson B, Syhakhang L, Lundborg CS, Eriksson B, Tomson G: Private pharmacy practice and regulation. A randomized trial in Lao P.D.R. Int J Technol Assess Health Care. 2001, 17 (4): 579-589.PubMed
Metadata
Title
"We noticed that suddenly the country has become full of MRI". Policy makers' views on diffusion and use of health technologies in Iran
Authors
Mohammad Palesh
Carol Tishelman
Sten Fredrikson
Hamidreza Jamshidi
Göran Tomson
Azita Emami
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Health Research Policy and Systems / Issue 1/2010
Electronic ISSN: 1478-4505
DOI
https://doi.org/10.1186/1478-4505-8-9

Other articles of this Issue 1/2010

Health Research Policy and Systems 1/2010 Go to the issue